Capecitabine in breast cancer: current status

Clinical Breast Cancer
C H SmorenburgJ Verweij

Abstract

Anthracyclines, together with taxanes, are at present the most active agents in metastatic breast cancer, while single-agent, bolus 5-fluorouracil (5-FU) is not very active in this setting. In view of encouraging results and tolerable toxicity of continuous infusion of 5-FU in gastrointestinal cancer, innovative oral 5-FU agents such as capecitabine have been developed. Capecitabine is a prodrug that is converted into the active compound 5-FU preferentially at the tumor site. An intermittent dosing schedule of capecitabine twice daily at a dose of 2510 mg/m2/day on days 1-14 in a 3-week cycle appeared to be feasible and resulted in a high dose intensity. A large phase II study investigating capecitabine in 135 advanced breast cancer patients, pretreated with anthracyclines and taxanes, observed three complete and 24 partial responses (response rate, 20%), with a mean duration of 8.0 months. Preliminary results of a study comparing capecitabine with paclitaxel in 42 breast cancer patients failing anthracyclines indicate that the efficacy of capecitabine is comparable to that of paclitaxel, with response rates of 36% and 21%, respectively. Another study reported a response rate of 25% for capecitabine as first-line therapy for ad...Continue Reading

References

Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E EngelsmanR Sylvester
Feb 1, 1991·American Journal of Clinical Oncology·C L LoprinziC J Allegra
Mar 15, 1989·Cancer·C L Loprinzi
Mar 16, 2001·Expert Opinion on Pharmacotherapy·J M NabholtzJ Mackey

❮ Previous
Next ❯

Citations

Jan 17, 2009·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lee S SchwartzbergArthur C Houts
May 23, 2014·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Junhyeon ChoSoohyeon Lee
Sep 1, 2007·Clinical & Experimental Ophthalmology·Gowri L KanthanR Max Conway
Nov 9, 2010·Dermatologic Therapy·Vincenzo De GiorgiTorello Lotti
Sep 21, 2002·Clinical Journal of Oncology Nursing·Susan Moore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.